ImmunoPrecise Antibodies Ltd (IPA)
1.18
+0.06
(+5.36%)
USD |
NASDAQ |
May 17, 16:00
1.19
+0.01
(+0.85%)
After-Hours: 20:00
ImmunoPrecise Antibodies EPS Diluted (Quarterly): -0.0814 for Jan. 31, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| January 31, 2024 | -0.0814 |
| October 31, 2023 | -0.0736 |
| July 31, 2023 | -0.1048 |
| April 30, 2023 | -0.1549 |
| January 31, 2023 | -0.1409 |
| October 31, 2022 | -0.2254 |
| July 31, 2022 | -0.295 |
| April 30, 2022 | -0.1814 |
| January 31, 2022 | -0.1578 |
| October 31, 2021 | -0.2067 |
| July 31, 2021 | -0.1383 |
| April 30, 2021 | -0.2381 |
| January 31, 2021 | -0.0622 |
| October 31, 2020 | -0.0227 |
| July 31, 2020 | -0.0292 |
| April 30, 2020 | -0.0509 |
| January 31, 2020 | -0.038 |
| October 31, 2019 | -0.0755 |
| July 31, 2019 | -0.1129 |
| April 30, 2019 | -0.2253 |
| January 31, 2019 | -0.0751 |
| October 31, 2018 | -0.0767 |
| July 31, 2018 | -0.0767 |
| April 30, 2018 | -0.1571 |
| January 31, 2018 | -0.1186 |
| Date | Value |
|---|---|
| October 31, 2017 | -0.0799 |
| July 31, 2017 | -0.0757 |
| April 30, 2017 | -0.1166 |
| January 31, 2017 | -0.9747 |
| September 30, 2016 | -0.0047 |
| June 30, 2016 | -0.0116 |
| March 31, 2016 | -0.0109 |
| December 31, 2015 | -0.0896 |
| September 30, 2015 | -0.0041 |
| June 30, 2015 | 0.0122 |
| March 31, 2015 | 0.0121 |
| December 31, 2014 | -0.0248 |
| September 30, 2014 | -0.0551 |
| June 30, 2014 | 0.0412 |
| March 31, 2014 | -0.0272 |
| December 31, 2013 | -0.0793 |
| September 30, 2013 | 0.2599 |
| June 30, 2013 | -0.0293 |
| March 31, 2013 | -0.0298 |
| December 31, 2012 | -0.121 |
| September 30, 2012 | -0.0301 |
| June 30, 2012 | -0.0149 |
| March 31, 2012 | -0.015 |
| December 31, 2011 | -0.2091 |
| September 30, 2011 | -0.1838 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.295
Minimum
Jul 2022
-0.0227
Maximum
Oct 2020
-0.1258
Average
-0.1129
Median
Jul 2019
EPS Diluted (Quarterly) Benchmarks
| Acasti Pharma Inc | -0.0542 |
| Aurinia Pharmaceuticals Inc | -0.18 |
| Edesa Biotech Inc | -0.58 |
| Lexaria Bioscience Corp | -0.06 |
| Xenon Pharmaceuticals Inc | -0.62 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.177M |
| Revenue (Quarterly) | 4.606M |
| Total Expenses (Quarterly) | 7.078M |
| Enterprise Value | 26.42M |
| Gross Profit Margin (Quarterly) | 51.39% |
| Profit Margin (Quarterly) | -47.26% |
| Earnings Yield | -35.15% |
| Normalized Earnings Yield | -35.02 |